Lipid-derived neutral nanoparticles

Patent metadata

Field	Value
Publication number	US-9877919-B2
Application number	US-201314389165-A
Country	US
Kind code	B2
Filing date	Mar 29, 2013
Priority date	Mar 29, 2012
Publication date	Jan 30, 2018
Grant date	Jan 30, 2018

Abstract

Disclosed herein are novel lipids and liposomal compositions prepared using such compounds and related methods of neutralizing or otherwise modifying such liposomal compositions. The lipids described herein are useful for example, as liposomal vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and the subsequent transfection of such target cells. In certain embodiments, one or more of the compounds that comprise the liposomal delivery vehicle may be neutralized or further modified such that the properties of the liposomal delivery vehicle are modified.

First claim

We claim:

1. A method of encapsulating one or more negatively charged nucleic acids in a neutral lipid nanoparticle, comprising the steps of:
(a) encapsulating one or more negatively charged nucleic acids within a lipid nanoparticle, wherein the lipid nanoparticle comprises:
a cationic lipid, the cationic lipid comprises a polar head-group bound to a lipophilic tail-group via a linker group, the polar head-group is exposed on the surface of the lipid nanoparticle, and the linker group is susceptible to chemical or enzymatic cleavage;
a PEG-modified lipid;
one or more non-cationic lipids that is zwitterionic or anionic; and
one or more non-cationic lipids that is neutral;

and
(b) modulating the surface of the lipid nanoparticle by subjecting the linker group to chemical or enzymatic cleavage; thereby releasing the polar head-group from the surface of the lipid nanoparticle.

2. The method of claim 1 , wherein the cationic lipid with the releasable polar head group is represented by the structural formula:

or a pharmaceutically acceptable salt thereof,
wherein:
R 1 is selected from the group consisting of imidazole; guanidinium; imine; enamine; amino; an alkyl amino optionally-substituted with alkyl, halo, alkoxy, hydroxyl, amino, aryl, ether, ester, or amide; or a pyridyl optionally substituted with alkyl, halo, alkoxy, hydroxyl, amino, aryl, ether, ester, or amide;
R 2 is selected from the group consisting of alkyl, alkenyl, acyl, pyridyl,

each optionally substituted with alkyl, halo, alkoxy, hydroxyl, amino, aryl, ether, ester, nitro, or amide;
R 3 and R 4 are each independently selected from the group consisting of C 6 -C 20 alkyl, C 6 -C 20 alkenyl, and C 6 -C 20 acyl, each optionally substituted with alkyl, halo, alkoxy, hydroxyl, amino, aryl, ether, ester, or amide; and
n is zero or any positive integer.

3. The method of claim 2 , wherein the modulating step comprises exposing the lipid nanoparticle to a reducing agent thereby cleaving the linker group and releasing the polar head-group from the lipophilic tail-group.

4. The method of claim 3 , wherein the reducing agent is tris (2-carboxyethyl)phosphine (TCEP), β-mercaptoethanol (β-ME), dithiothreitol (DTT), glutathione, dithioerythritol, or any combinations thereof.

5. The method of claim 2 , wherein the modulating step comprises exposing the lipid nanoparticle to an enzyme thereby cleaving the linker group and releasing the polar head-group from the lipophilic tail-group.

6. The method of claim 5 , wherein the enzyme is selected from the group consisting of alkaline phosphatase, carboxypeptidase G2, cytosine deaminase, nitroreductase, β-glucuronidase, α-galactosidase, thioredoxin, and gamma-interferon inducible lysosomal thiol reductase (GILT).

7. The method of claim 1 , wherein the one or more negatively charged nucleic acids are selected from mRNA, siRNA, snoRNA, microRNA or any combination thereof.

8. The method of claim 7 , wherein the one or more negatively charged nucleic acids are mRNA.

9. The method of claim 8 , wherein the mRNA comprises at least one modified nucleotide independently selected from the group consisting of 5-methylcytosine, isocytosine, pseudoisocytosine, 5-bromouracil, 5-propynyluracil, 6-aminopurine, 2-aminopurine, inosine, pseudouridine, 2-thiouridine, diaminopurine and 2-chloro-6-aminopurine cytosine.

10. The method of claim 8 , wherein the mRNA comprises one or more nucleotide modifications selected from the group consisting of: Locked Nucleic Acid (LNA); 2′-O-alkyl-RNA units, 2′-OMe-RNA units, 2′-amino-DNA units, and 2′-fluoro-DNA units.

11. The method of claim 1 , wherein the method results in an encapsulation efficiency of at least 65%.

12. The method of claim 1 , wherein the method results in an encapsulation efficiency of at least 75%.

13. The method of claim 1 , wherein the modulating step results in reducing average zeta potential of the surface to less than about −0.5 mV.

14. The method of claim 1 , wherein the modulating step results in reducing average zeta potential of the surface to between about −2.5 mV and +2.5 mV.

15. The method of claim 1 , wherein the method results in an encapsulation efficiency of at least 55%.

Assignees

• Translate Bio Inc

Inventors

• Derosa Frank
• Guild Braydon Charles
• Heartlein Michael

Classifications

• A61K9/1272

  comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543}) · CPC title

• C12N2310/11

  Antisense · CPC title

• C12N2310/3515

  Lipophilic moiety, e.g. cholesterol · CPC title

• C12N15/111

  General methods applicable to biologically active non-coding nucleic acids · CPC title

• A61K47/28

  Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid · CPC title